Revvity, Inc. (NYSE: RVTY) announced that it will acquire ACD/Labs, a global provider of analytical chemistry and molecular design software, for an estimated $70 million in cash. The definitive agreement, signed on November 10 2025, is expected to close in the fourth quarter of 2025 and will add ACD/Labs’ deep expertise in analytical and process chemistry to Revvity’s Signals software franchise.
The acquisition is designed to create a unified, end‑to‑end SaaS platform that connects molecular design, analytical science, and manufacturing quality control. By integrating ACD/Labs’ Spectrus® and Percepta® platforms, Revvity will offer scientists a single environment that spans discovery through production, thereby strengthening its position in the high‑growth scientific software market and reinforcing its strategy of delivering differentiated, high‑margin technology solutions.
Financially, the deal is projected to be earnings‑per‑share neutral in 2026 and accretive thereafter, adding roughly $20 million in annual revenue. The $70 million purchase price is expected to be financed through a mix of cash and debt, with no immediate impact on Revvity’s liquidity profile. The transaction is also expected to broaden Revvity’s customer base in pharmaceuticals and material sciences, providing new cross‑sell opportunities within its existing life‑sciences and diagnostics segments.
Revvity’s recent performance underscores the strategic timing of the acquisition. In the third quarter of 2025, the company reported revenue of $699 million, a 1 % organic increase, and an adjusted EPS of $1.18, beating consensus by $0.04. The revenue miss was driven by a decline in legacy diagnostics sales, while the EPS beat reflected disciplined cost management and a favorable mix shift toward higher‑margin software contracts. However, Revvity continues to face declining revenue growth and operating margins, prompting the company to pursue acquisitions that can accelerate its software portfolio and improve profitability.
Kevin Willoe, president of Revvity Signals Software, said the integration will “give our customers across pharmaceuticals and material sciences a truly unified SaaS environment—one that connects molecular design, analytical science, and manufacturing quality control within a single, end‑to‑end solution.” Daria Thorp, president and CEO of ACD/Labs, added that the partnership “brings together two industry leaders with a shared commitment to innovation in scientific software, expanding the reach of our technology and delivering unified, end‑to‑end solutions that empower customers with deeper insight and greater scientific continuity.”
The acquisition addresses Revvity’s margin compression by adding high‑margin analytical software to its portfolio, while also positioning the company to capture growth in the expanding AI‑driven scientific software market. By combining ACD/Labs’ analytical capabilities with Revvity’s existing life‑sciences platform, the company aims to create a more compelling value proposition for customers, potentially offsetting the headwinds it faces in its diagnostics segment and supporting long‑term revenue and earnings growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.